Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer

Purpose and Methods: Resistance to alkylating agents and platinum compounds is associated with elevated levels of glutathione (GSH). Depletion of GSH by buthionine sulfoximine (BSO) restores the sensitivity of resistant rumors to melphalan in vitro and in vivo. In a phase I trial, each patient received two cycles as follows: BSO alone intravenously (IV) every 12 hours for six doses, and 1 week later the same BSO as cycle one with melphalan (L-PAM) 15 mg/m(2) IV 1 hour after the fifth dose. BSO doses were escalated from 1.5 to 17 g/m(2) in 41 patients. Results: The only toxicity attributable to BSO was grade I or II nausea/vomiting in 50% of patients. Dose-related neutropenia required an L-PAM dose reduction to 10 mg/m(2) at BSO 7.5 g/m(2). We measured GSH in peripheral mononuclear cells (PMN), and in tumor biopsies when available, at intervals following BSO dosing. In PMNs, GSH content decreased over 36 to 72 hours to reach a nadir on day 3; at the highest dose, recovery was delayed beyond day 7. The mean PMN GSH nadirs were approximately 10% of control at BSO doses greater than or equal to 7.5 g/m(2); at 13 and 17 g/m(2), all but two patients had nadir values in this range. GSH was depleted in sequential tumor biopsies to a variable extent, but with a similar time course. At BSO doses greater than or equal to 13 g/m(2), tumor GSH was less than or equal to 20% of starting values on day 3 in five of seven patients; recovery had not occurred by day 5. We measured plasma concentrations of R- and S-BSO by high-performance liquid chromotography (HPLC) in 22 patients throughout the dosing period. Total-body clearance (CL(dagger)) and volume of distribution at steady-state (V-ss) for both isomers were dose-independent. The CL(dagger) of S-BSO was significantly less than that of R BSO at all doses, but no significant differences in V-ss were observed between the racemates. Harmonic mean half-lives were 1.39 hours and 1.89 hours for R-BSO and S-BSO, respectively. Conclusion: A biochemically appropriate dose of BSO for use on this schedule is 13 g/m(2), which will be used in phase II trials to be conducted in ovarian cancer and melanoma. (C) 1996 by American Society of Clinical Oncology.